Esophageal cancer. Malignant neoplasm of lower third of esophagus
Conditions
Interventions
Intervention 1: Intervention group: chemotherapy with oxaliplatin (85 mg/m2, week 1, 3, 5) + capecitabine (625mg/m2, BD, day 1 to 5, weekly), during radiotherapy. Intervention 2: Control group: chemot
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Tumor should located in thoracic esophagus or gastro-esophageal junction. Patients' age should be between 18-75 years old. Pathology consists of squamous cell carcinoma or adenocarcinoma. Tumor should be resectable. Disease should be curable.
Exclusion criteria
Exclusion criteria: Patient who suffers from bad performance status.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor regression grade. Timepoint: Tumor regression grade will determine once after surgery. Method of measurement: Tumor regression grade will determine through surgical sample by pathologist. | — |
Secondary
| Measure | Time frame |
|---|---|
| Gastrointestinal adverse effects. Timepoint: Gastrointestinal adverse effects will be evaluated at 1 and 3 months after neo-adjuvant chemoradiation. Method of measurement: Gastrointestinal adverse effects will be evaluated through CTCAE (Common Terminology Criteria for Adverse Events).;Hematologic adverse effects. Timepoint: Hematologic adverse effects will be evaluated at 1 and 3 months after neo-adjuvant chemoradiation. Method of measurement: Hematologic adverse effects will be evaluated through CTCAE (Common Terminology Criteria for Adverse Events).;Surgical margin's tumor remnant. Timepoint: Surgical margin's tumor remnant is determined once after surgery. Method of measurement: Surgical margin's tumor remnant is determined through pathologist's assessment. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBorna Farazmand
Tehran University of Medical Sciences
Outcome results
None listed